Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation

Head and Neck

Volumn 35, Issue 12, 2013, Pages 1698-1706

  Broglie, Martina A ^a   Soltermann, Alex ^b   Rohrbach, David ^b   Haile, Sarah R ^c   Pawlita, Michael ^d   Studer, Gabriela ^b   Huber, Gerard F ^b   Moch, Holger ^b   Stoeckli, Sandro J ^a  

^a Kantonsspital StGallen ^*  (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

alcohol; HPV; intensity modulated radiotherapy; oropharyngeal squamous cell carcinoma; outcome; p16; p53; risk stratification; smoking; survival

Indexed keywords

PROTEIN P16; PROTEIN P53;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RISK FACTOR; SMOKING; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY;

ALCOHOL; HPV; INTENSITY MODULATED RADIOTHERAPY; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OUTCOME; P16; P53; RISK STRATIFICATION; SMOKING; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ALGORITHMS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; OROPHARYNGEAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, INTENSITY-MODULATED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; SMOKING; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84888004601     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23231     Document Type: Article

References (42)

1. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-1131.
2. Snijders PJ, Cromme FV, van den Brule AJ, et al. Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer 1992; 51: 845-850.
3. Gillison ML,. Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J Clin Oncol 2006; 24: 5623-5625.
4. Andl T, Kahn T, Pfuhl A, et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998; 58: 5-13.
5. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003; 107: 394-400.
6. Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004; 96: 998-1006.
7. Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH,. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 2003; 9: 6469-6475.
8. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
9. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010; 16: 1226-1235.
10. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
11. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM,. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001; 92: 805-813.
12. Mendenhall WM, Amdur RJ, Palta JR,. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006; 24: 2618-2623.
13. Tribius S, Bergelt C,. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain? Cancer Treat Rev 2011; 37: 511-519.
14. Garden AS, Morrison WH, Wong PF, et al. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007; 67: 438-444.
15. Studer G, Huguenin PU, Davis JB, Kunz G, Lütolf UM, Glanzmann C,. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients. Radiat Oncol 2006; 1: 7.
16. Mendenhall WM, Amdur RJ, Morris CG, Kirwan JM, Li JG,. Intensity-modulated radiotherapy for oropharyngeal squamous cell carcinoma. Laryngoscope 2010; 120: 2218-2222.
17. Röösli C, Tschudi DC, Studer G, Braun J, Stoeckli SJ,. Outcome of patients after treatment for a squamous cell carcinoma of the oropharynx. Laryngoscope 2009; 119: 534-540.
18. Wittekind C, Compton CC, Greene FL, Sobin LH,. TNM residual tumor classification revisited. Cancer 2002; 94: 2511-2516.
19. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
20. Daly ME, Lieskovsky Y, Pawlicki T, et al. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head Neck 2007; 29: 211-220.
21. Hodge CW, Bentzen SM, Wong G, et al. Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison. Int J Radiat Oncol Biol Phys 2007; 69: 1032-1041.
22. Saba NF, Edelman S, Tighiouart M, et al. Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis. Head Neck 2009; 31: 1447-1455.
23. Allen CT, Lewis JS Jr, El-Mofty SK, Haughey BH, Nussenbaum B,. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010; 120: 1756-1772.
24. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747.
25. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 2465-2472.
26. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120: 1731-1738.
27. Ukpo OC, Flanagan JJ, Ma XJ, Luo Y, Thorstad WL, Lewis JS Jr,. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol 2011; 35: 1343-1350.
28. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27: 6213-6221.
29. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008; 122: 2656-2664.
30. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.
31. Mellin H, Dahlgren L, Munck-Wikland E, et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 2002; 102: 152-158.
32. Franceschi S, Talamini R, Barra S, et al. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res 1990; 50: 6502-6507.
33. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-3287.
34. Haddad RI, Shin DM,. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-1154.
35. Vogelstein B, Lane D, Levine AJ,. Surfing the p53 network. Nature 2000; 408: 307-310.
36. Gasco M, Crook T,. The p53 network in head and neck cancer. Oral Oncol 2003; 39: 222-231.
37. Smith EM, Wang D, Rubenstein LM, Morris WA, Turek LP, Haugen TH,. Association between p53 and human papillomavirus in head and neck cancer survival. Cancer Epidemiol Biomarkers Prev 2008; 17: 421-427.
38. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11: 5856-5862.
39. Aebersold DM, Froehlich SC, Jonczy M, et al. Expression of transforming growth factor-alpha, epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. Radiother Oncol 2002; 63: 275-283.
40. Kim SH, Koo BS, Kang S, et al. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer 2007; 120: 1418-1425.
41. Mowry SE, Tang C, Sadeghi A, Wang MB,. Standard chemoradiation versus intensity-modulated chemoradiation: a quality of life assessment in oropharyngeal cancer patients. Eur Arch Otorhinolaryngol 2010; 267: 1111-1116.
42. Furness S, Glenny AM, Worthington HV, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev 2011; CD006386.